Posted by Michael Wonder on 23 May 2019
Health Canada approves Mylan and Biocon's Ogivri, the first trastuzumab biosimilar, for the treatment of HER2-positive breast and gastric cancers
22 May 2019 - Ogivri is a part of Mylan's robust portfolio of 20 biosimilar and insulin analog products.
Mylan and Biocon today announced that Health Canada has approved Mylan's Ogivri (trastuzumab), a biosimilar to Herceptin (trastuzumab) co-developed with Biocon, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastro-oesophageal junction adenocarcinoma).
Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Mylan and Biocon's joint portfolio approved in the market. Mylan plans to launch the product this quarter and anticipates potentially being the first company to offer a trastuzumab biosimilar in Canada.
